Evidence map›Paper›PMID 35602299›Full record

ArticleJournal of oncology2022

A N

Wangli Mei, Xuyang Jia, Shiyong Xin, Xiang Liu, Liang Jin, Xianchao Sun, Jia-Xin Zhang, Bihui Zhang, Guosheng Yang, Ping Chen and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Wangli Mei *Department of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0002-0488-2149
Xuyang Jia *Department of Metabolic Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.ORCID https://orcid.org/0000-0003-4688-6778
Shiyong XinDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0002-6015-8665
Xiang LiuDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0003-4426-1985
Liang JinDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China.ORCID https://orcid.org/0000-0003-1854-1692
Xianchao SunDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0002-7375-7712
Jia-Xin ZhangDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0001-8495-8459
Bihui ZhangDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0003-3602-9617
Guosheng YangDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0003-4495-2874
Ping ChenSchool of Life Science and Technology, Tongji University, Shanghai 200092, China.ORCID https://orcid.org/0000-0002-1102-6519
Lin YeDepartment of Urology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.ORCID https://orcid.org/0000-0002-3304-4558
Tongji University · CNShanghai East Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite the constant iteration of small-molecule inhibitors and immune checkpoint inhibitors, PRAD (prostate adenocarcinoma) patients with distant metastases and biochemical recurrence maintain a poor survival outcome along with an increasing morbidity in recent years. N Methods: 42 genes related to m Results: The m Conclusions: A m

Identifiers

PMID35602299
PMCPMC9122703
OpenAlexW4280644274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.